Cytek BioSciences Inc [CTKB] stock prices are up 0.37% to $5.45 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CTKB shares have gain 10.77% over the last week, with a monthly amount glided 12.37%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, TD Cowen downgraded its rating to Hold on May 09, 2025, and kept the price target unchanged to $4. On January 31, 2025, downgrade downgraded it’s rating to Sell and revised its price target to $4.50 on the stock. Stephens started tracking the stock assigning a Overweight rating and suggested a price target of $9 on December 14, 2023. Raymond James initiated its recommendation with a Mkt Perform.
The stock price of Cytek BioSciences Inc [CTKB] has been fluctuating between $2.37 and $7.30 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Cytek BioSciences Inc [NASDAQ: CTKB] shares were valued at $5.45 at the most recent close of the market. An investor can expect a potential return of 10.09% based on the average CTKB price forecast.
Analyzing the CTKB fundamentals
The Cytek BioSciences Inc [NASDAQ:CTKB] reported sales of 196.83M for trailing twelve months, representing a surge of 1.54%. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -0.14%, Pretax Profit Margin comes in at -0.04%, and Net Profit Margin reading is -0.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.01, Equity is -0.02 and Total Capital is -0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Cytek BioSciences Inc [NASDAQ:CTKB]’s Current Ratio is 5.17. Also, the Quick Ratio is 4.48, while the Cash Ratio stands at 1.03. Considering the valuation of this stock, the price to sales ratio is 3.53, the price to book ratio is 1.84.
Transactions by insiders
Recent insider trading involved McCombe William D., Chief Financial Officer, that happened on Jun 02 ’25 when 35000.0 shares were purchased.
